CHCWM – Cancer & Hematology Centers of West Michigan

INBRX-106 (InhibRx)

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors